Use Able AI chat for product recommendations

Recombinant Human FGFR3 (IIIb) protein (hFc Tag, Myc Tag, His Tag)(HPLC verified)

Species

Human

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

hFc Tag, Myc Tag, His Tag

Activity

EC50: 95-380 ng/mL

Cat no : Eg0194



Product Information

Purity >90 %, SDS-PAGE
>90 %, SEC-HPLC
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Immobilized Human FGF basic (His tag) at 1 μg/mL (100 μL/well) can bind Human FGFR3 (IIIb) (hFc tag, Myc tag, His tag) with a linear range of 95-380 ng/mL.
Expression HEK293-derived Human FGFR3 (IIIb) protein Glu23-Gly377 (Accession# P22607-2) with a human IgG1 Fc tag, a Myc tag and a His tag at the C-terminus.
GeneID 2261
Accession P22607-2
PredictedSize 67.1 kDa
SDS-PAGE 85-100 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

FGFR3 (Fibroblast growth factor receptor 3) is a tyrosine-protein kinase that that acts as cell-surface receptor for fibroblast growth factors. FGFR3 binds acidic and basic fibroblast GH and plays important roles in development, osteogenesis, and bone maintenance. FGFR3 is highly expressed in chondrocytes and osteoblasts, and germline mutations are associated with bone growth disorders such as achondroplasia, chondrodysplasia, and thanatophoric dysplasia. Due to frequent mutations in certain cancers, FGFR3 gene has also been associated with tumor progression.

References:

1.Eswarakumar VP, et al. (2005). Cytokine Growth Factor Rev. 16(2):139-149. 2.Tiong KH, et al. (2013). Apoptosis. 18(12):1447-1468. 3.Kacew A, et al. (2020). Front Immunol. 11:575258. 4.Horton WA, et al. (2007). Lancet. 370(9582):162-172.

||
New chat

Able™

正在加载,请稍候...